The SOGC / GOC 2021 guidelines are in effect in the Trophoblastic Diseases Unit (UMT) of the gynecology oncology department of the CHUM.

However, clinical judgment remains paramount and each patient must be managed individually.

Statement

The authors have prepared this guideline under the direction of the Guidelines Committee of the Society of Gynecologic Oncology of Canada (GOC) and the Clinical Practice – Gynecology Committee of the Society of Obstetricians and Gynecologists of Canada (SOGC). Members of the SOGC's Guidelines Management and Oversight Committee and Family Physician Advisory Committee reviewed it before the GOC Executive and Board of Directors and the SOGC Board of Directors approve it.

Lua Eiriksson, MD, Hamilton, ON; Erin Dean, MD, Winnipeg, MB; Alexandra Sebastianelli, MD, Quebec, QQ; Shannon Salvador, MD, Montreal, QC; Robyn Comeau, MD, Moncton, NB; Ji-Hyun Jang, MD, Vancouver, BC; Genevieve Bouchard-Fortier, MD, Toronto; ON, Ray Osborne, MD, Toronto, ON; Philippe Sauthier, MD, Montreal, QC.

Introduction

• Objective : The clinical evaluation and management of gestational trophoblastic diseases (GTD), including surgical and drug treatments for benign, premalignant and malignant tumours.
• Target population : Women of childbearing age with gestational trophoblastic disease.
• Principles : Women diagnosed with GTD should be referred to a gynecologist; women diagnosed with gestational trophoblastic neoplasia (GTN) should be referred to a gynecologist-oncologist. It is recommended that each case of GTN be discussed at a multidisciplinary oncology meeting and entered into a centralized (regional and/or national) database.

Organization

• Joint SOGC-GOC Clinical Guideline
• 15 Recommendations (GRADE Rating)
• 9 Summary Statements (GRADE Rating)
• 5 Key Messages
• 3 Recommended Practice Changes